Good to read your thoughts on the upcoming approval decision; I believe most people here feel as you do, that DCVax will be approved. "nothing will change on approval"
Now about your latest comment: "Better ways to charity than flushing your money in[to] NWBO [an] inept crew." Seems a bit over the top.
NWBO is the first company in +20 years to have a successful GBM trial, the last +300 trials failed. That's quite an accomplishment, for any biotech business, especially a startup pre-revenue biotech. The fact that they stayed the course over the many years this trial has taken, to obtain indisputable evidence of long-term efficacy, whilst battling Wall Street forces intent on their destruction, speaks volumes to the ability of this "crew". I'm not aware of any other company having a treatment platform on the cusp of approval that many feel will be applicable to most solid tumor cancers. The Roswell cancer institute has entrusted their dendritic cell portfolio to NWBO for Devlopment. The market research group Delve Insight has DCVax as the #1 treatment for GBM through 2030. (https://www.delveinsight.com/report-store/dcvax-l-emerging-drug-insight-and-market-forecast). Not sure why you are here, other than the obvious. __________________________________________________ Not to be taken as investment advice - Do your own due diligence.
Market Data 
Markets 
AI
